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Peroxisome proliferator-activated receptor (PPAR) g
coactivator-1b (PGC-1b) is a transcriptional coacti-
vator that induces hypertriglyceridemia in response
to dietary fats through activating hepatic lipogenesis
and lipoprotein secretion. The expression of PGC-1b
is regulated by free fatty acids. Here we show that
PGC-1b regulates plasma triglyceride metabolism
through stimulating apolipoprotein C3 (APOC3)
expression and elevating APOC3 levels in circulation.
Remarkably, liver-specific knockdown of APOC3
significantly ameliorates PGC-1b-induced hypertri-
glyceridemia in mice. Hepatic expression of
PGC-1b and APOC3 is reduced in response to acute
and chronic treatments with nicotinic acid, a widely
prescribed drug for lowering plasma triglycerides.
Adenoviral-mediated knockdown of PGC-1b or
APOC3 in the liver recapitulates the hypolipidemic
effect of nicotinic acid. Proteomic analysis of hepatic
PGC-1b transcriptional complex indicates that it
stimulates APOC3 expression through coactivating
orphan nuclear receptor ERRa and recruiting chro-
matin-remodeling cofactors. Together, these studies
identify PGC-1b as an important regulator of the
APOC3 gene cluster and reveal a mechanism
through which nicotinic acid achieves its therapeutic
effects.
INTRODUCTION
Elevated plasma triglyceride levels are a central component of
dyslipidemia in metabolic syndrome and serve as an indepen-
dent risk factor for cardiovascular disease (Brunzell, 2007; Co-
hen et al., 1998; Goldberg, 2001). Hypertriglyceridemia results
from an imbalance of the production and catabolism of triglyc-
eride-rich lipoprotein particles, particularly very-low-density
lipoprotein (VLDL). Genetic analyses of familial lipoprotein disor-
ders as well as recent genome-wide association studies have re-
vealed a number of candidate factors that contribute to the path-
ogenesis of hypertriglyceridemia (Breslow, 2000; Kathiresan
et al., 2008; Saxena et al., 2007; Willer et al., 2008). Notably,Cellsingle-nucleotide polymorphisms within the apolipoprotein
(APO) gene cluster, which includes APOA1/C3/A4/A5 genes,
have been repeatedly identified as risk alleles associated with
hypertriglyceridemia in humans (Lai et al., 2005; van Dijk et al.,
2004). Among these apolipoproteins, APOC3 and APOA5 have
opposing effects on plasma triglyceride metabolism (van Dijk
et al., 2004). Transgenic expression of APOC3 in mouse livers
leads to pronounced hypertriglyceridemia, likely through inhibit-
ing lipases that hydrolyze VLDL triglycerides, whereas deletion
of APOC3 lowers plasma triglyceride levels in mice (Ito et al.,
1990; Maeda et al., 1994). In contrast, APOA5 appears to have
opposite effects on plasma triglyceride metabolism (Pennacchio
et al., 2001). As such, balanced expression of apolipoprotein
genes within this locus, particularly APOC3 and APOA5, is pre-
dicted to significantly influence plasma triglyceride homeostasis.
PGC-1b is amember of the PGC-1 family of transcriptional co-
activators that regulates mitochondrial oxidative metabolism
and diverse biological processes (Finck and Kelly, 2006; Hand-
schin, 2009; Lin et al., 2005a). In the liver, PGC-1a regulates
hepatic fasting response and coordinates key aspects of circa-
dian metabolic rhythms (Lin et al., 2004; Liu et al., 2007; Yoon
et al., 2001). We have previously shown that PGC-1b induces
hyperlipidemia in response to dietary fats through enhancing
hepatic lipogenesis and VLDL secretion (Lin et al., 2005b). The
expression of PGC-1b is increased in the liver in response to
short-term high-fat diet feeding in mice. Several factors have
been demonstrated to interact with PGC-1b and stimulate
hepatic lipogenesis and lipoprotein secretion, including sterol-
response element binding protein (SREBP), liver-X receptor
(LXR), and Foxa2 (Lin et al., 2005b; Wolfrum and Stoffel, 2006).
Interestingly, systemic delivery of antisense oligonucleotide tar-
geting PGC-1b leads to improvedmetabolic profile in the context
of fructose-induced insulin resistance (Nagai et al., 2009). Given
the prominent role of APOC3 and APOA5 in plasma triglyceride
metabolism, we hypothesized that PGC-1b may regulate lipo-
protein homeostasis through impinging on the APO gene cluster.
In the current study, we investigated the role of PGC-1b in
apolipoprotein gene expression and determined the significance
of APOC3 in mediating the hypertriglyceridemic effects of
PGC-1b using in vivo RNAi knockdown. We also identified the
PGC-1b/APOC3 pathway as a key hepatic target of nicotinic
acid, a commonly prescribed triglyceride-lowering drug. Finally,
we performed proteomic studies on PGC-1b transcriptional
complexes isolated from mouse liver and identified transcrip-
tional components that mediate the induction of APOC3 by
PGC-1b.Metabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Inc. 411
Figure 1. Induction of APOC3 Expression by PGC-1b in the Liver and Cultured Primary Hepatocytes
(A) Plasma triglyceride and NEFA levels and liver triglyceride content in mice transduced with Ad-GFP (open) or Ad-PGC-1b (filled). *p < 0.01.
(B) Real-time PCR analysis of total liver RNA from mice transduced with Ad-GFP or Ad-PGC-1b. Shown is fold induction versus Ad-GFP group. Data represent
mean ± SEM (n = 4). *p < 0.05; **p < 0.01; ***p < 0.001.
(C) Immunoblot analysis of APOC3 and APOB proteins in serum samples and PGC-1b in liver nuclear extracts from mice transduced with Ad-GFP or Ad-PGC-1b
(n = 4). Ponceau S staining and Lamin immunoblot were shown as loading control for serum and nuclear extracts, respectively.
(D) Real-time PCR analysis of total RNA from primary hepatocytes transduced with Ad-GFP (open) or Ad-PGC-1b (filled). Shown is fold induction versus Ad-GFP
group. Data represent mean ± SD from a representative experiment. *p < 0.05; ***p < 0.001.
Cell Metabolism
Hepatic PGC-1b/ApoC3 Mediates Nicotinic Acid ActionRESULTS
PGC-1b Induces Hepatic APOC3 Expression
and Elevates Its Plasma Levels
To determine whether PGC-1b regulates APO gene expression,
we transduced C57BL/6J mice with recombinant adenoviral
vectors expressing control (Ad-GFP) or PGC-1b (Ad-PGC-1b)
via tail vein injection. Hepatic expression of PGC-1b significantly
increases plasma triglyceride concentrations without affecting
nonesterified fatty acid (NEFA) levels (Figure 1A). Unlike high-
fat-fed mice, liver triglyceride content is not affected by
PGC-1b in chow-fed mice. Gene expression analysis indicates
that PGC-1b increases APOC3 mRNA levels by approximately
2-fold in the liver, while reducing APOA5 gene expression
(Figure 1B). The expression of APOA1 and APOA4 is also
decreased by PGC-1b. PGC-1b induces the expression of
several genes involved in triglyceride synthesis, including diacyl-
glycerol o-acyltransferase 1 (Dgat1), glycerol-3-phosphate acyl-
transferase (Gpat), and glycerol kinase (GyK), as well as CideB,
a factor recently found to regulate VLDL secretion (Ye et al.,
2009). Consistently, immunoblotting analysis revealed that circu-
lating APOC3 levels are significantly elevated in the plasma from
mice transducedwith Ad-PGC-1b (Figure 1C). In contrast, APOB
protein levels (APOB48 and APOB100) remain largely unaltered.
Similar to in vivo studies, PGC-1b stimulates APOC3 expres-
sion in transduced primary hepatocytes (Figure 1D). Compared412 Cell Metabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Into GFP control, mRNA levels of CideB, Dgat1, Dgat2, and
GPAT are also elevated by PGC-1b. Unexpectedly, mRNA
expression of APOA1, A4, and A5 is increased by PGC-1b in
transduced hepatocytes, suggesting that certain physiological
signals that impact on APO gene expression might be lacking
in culture conditions. APOC3 is an inhibitor of lipoprotein lipases
and suppresses triglyceride hydrolysis, whereas APOA5
appears to play an opposite role (Merkel et al., 2005; Wang
et al., 1985). The induction of APOC3 by PGC-1b is consistent
with its ability to elevate plasma triglyceride levels. Together,
these results suggest that altered balance of apolipoproteins
may contribute to PGC-1b-induced hypertriglyceridemia. In
addition, this factor appears to differentially regulate the tran-
scription of individual APO genes within the APOA1/C3/A4/A5
cluster.
Induction of APOC3 Is Required for PGC-1b-Induced
Hypertriglyceridemia
To determine the significance of APOC3 induction by PGC-1b in
mediating hypertriglyceridemia, we used an RNAi knockdown
approach to modulate APOC3 expression in the liver. We con-
structed a recombinant adenovirus that expresses a short
hairpin RNA (shRNA) directed toward mouse APOC3 (siAPOC3).
Compared to control, siAPOC3 adenovirus significantly reduces
APOC3 mRNA levels in transduced primary hepatocytes (data
not shown). We next transduced mice with Ad-GFP orc.
Figure 2. Requirement of APOC3 in PGC-1b-Induced Hypertriglyceridemia
(A) Plasma triglyceride and NEFA concentrations and liver triglyceride content in mice transduced with Ad-GFP or Ad-PGC-1b in combination with control (open)
or siAPOC3 (filled) adenoviruses, as indicated. Four mice were included for each treatment. *p < 0.01; **p < 0.01. See also Figure S1.
(B) Immunoblots of serum samples and liver nuclear extracts from mice transduced with indicated adenoviruses.
(C) Lipoprotein profile analysis. Plasma was fractionated by FLPC, and triglyceride and cholesterol content in each fraction was measured.
(D)Plasma triglycerideandNEFAconcentrationsand liver triglyceridecontent inmice transducedwith scrb+GFP (open), siPGC-1b+GFP (filled), or siPGC-1b+APOC3
(blue) adenoviral mixtures, as indicated.
(E) qPCR analysis of liver gene expression in transducedmice. Data in (D) and (E) represent mean ± SEM (n = 5). *p < 0.05 scrb versus siPGC-1b; **p < 0.01 siPGC-
1b versus siPGC-1b+APOC3.
(F) Immunoblots of APOC3 in serum samples and PGC-1b liver nuclear extracts from transduced mice.
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adenoviruses. As expected, hepatic expression of PGC-1b
increases total plasma triglycerides by approximately 4.7-fold.
RNAi knockdown of APOC3 in the liver severely blunts PGC-
1b-mediated hypertriglyceridemia by approximately 50%
(Figure 2A). Gene expression analysis indicates that siAPOC3
reduces APOC3mRNA expression and circulating APOC3 levels
in transduced mice (Figure 2B and see Figure S1A available on-
line). In contrast, the expression of APOA5 and other PGC-1b
target genes, including CideB and Dgat1, is largely unaffected
by siAPOC3 treatment. Lipoprotein profile analyses revealed
that PGC-1b increases triglyceride concentrations almost exclu-
sively in the VLDL fractions (Figure 2C). Normalization of plasma
APOC3 levels with siAPOC3 significantly reduces VLDL triglyc-
eride content. Interestingly, hepatic expression of PGC-1b also
increases VLDL cholesterol, while reducing HDL cholesterolCellcontent. RNAi knockdown of APOC3 has modest effects on
HDL cholesterol, whereas it lowers VLDL cholesterol content in
both control and PGC-1b groups (Figure S1B).
We next examined whether PGC-1b is required for APOC3
expression and triglyceride regulation. Consistent with
a previous report (Lin et al., 2005b), RNAi knockdown of
PGC-1b reduces plasma triglyceride levels following two days
of high-fat feeding in transduced mice (Figure 2D). Hepatic
APOC3 mRNA expression and circulating APOC3 protein levels
were also decreased by expression of PGC-1b shRNA in the liver
(Figures 2E and 2F). To determine if decreased APOC3 is
responsible for lowering plasma triglyceride levels when
PGC-1b is inhibited, we performed ‘‘rescue’’ studies using an
adenoviral vector expressing mouse APOC3. As shown in
Figures 2D–2F, re-expression of APOC3 to levels slightly above
its endogenous levels completely blocks triglyceride-loweringMetabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Inc. 413
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that the regulation of APOC3 by PGC-1b plays an important role
in mediating its effects on plasma triglyceride metabolism.
Acute and Chronic Treatments with Nicotinic Acid
Suppress Hepatic PGC-1b and APOC3 Expression
Fibrates and nicotinic acid (niacin) are the two most commonly
prescribed drugs for the treatment of hypertriglyceridemia
(Brunzell, 2007; Gille et al., 2008). Fibrates act through nuclear
receptor PPARa and stimulate fatty acid b-oxidation in periph-
eral tissues (Lefebvre et al., 2006). The therapeutic target of
nicotinic acid remained elusive until recently with the discovery
of G protein-coupled receptor GPR109A (also known as
PUMAG and HM74) as its target (Soga et al., 2003; Tunaru
et al., 2003; Wise et al., 2003). Binding of nicotinic acid to
GPR109A leads to inhibition of lipolysis in adipocytes and
lowers free fatty acids released by the adipose tissue. While it
has been proposed that decreased circulating fatty acids
contribute to reduced hepatic VLDL secretion and plasma
triglycerides (Gille et al., 2008; Karpe and Frayn, 2004; Wang
et al., 2001), the regulatory pathways that nicotinic acid
engages to alter plasma lipid homeostasis are poorly under-
stood. We have previously demonstrated that the expression
of PGC-1b is responsive to fatty acids (Lin et al., 2005b). As
such, we hypothesized that this coactivator may serve as
a target for nicotinic acid action and mediate its therapeutic
effects through modulating lipoprotein metabolism.
We next examined whether the expression of PGC-1b is regu-
lated by acute and chronic nicotinic acid treatments. As ex-
pected, intraperitoneal injection of nicotinic acid caused a rapid
decrease of circulating NEFA levels (Figure S2A). While we
observed a trend for plasma triglyceride to be lower immediately
following a single dose of nicotinic acid administration, the data
did not reach statistical significance. Gene expression analysis
indicates that PGC-1a mRNA levels remain largely unchanged
throughout this study. In contrast, PGC-1b mRNA as well as
protein levels are significantly reduced 4 hr following this treat-
ment (Figures 3A and 3B). We did not observe a decrease of
PGC-1bmRNA expression at earlier time points, likely reflecting
the lag for fatty acids to exert their effects on PGC-1b gene
expression in the liver. Consistent with a non-cell-autonomous
mechanism, nicotinic acid does not alter PGC-1bmRNA expres-
sion in cultured primary hepatocytes (Figure S2B). To further
evaluate the chronic effects of nicotinic acid, we fed C57BL/6J
mice with a high-fat diet with or without 1% nicotinic acid, as
previously described (Hernandez et al., 2007). Chronic nicotinic
acid treatment lowers plasma triglyceride and free fatty acid
concentrations by 46% and 17%, respectively (Figure 3C).
Compared to control diet, the expression of PGC-1b and
APOC3 is significantly lower in the nicotinic acid-treated group
(Figures 3D and 3E). Accordingly, circulating APOC3 protein
levels are reduced in response to nicotinic acid. APOA5 and
PGC-1a mRNA levels are also reduced in response to chronic
niacin treatments.
Inhibition of Hepatic PGC-1b and APOC3 Mediates
Triglyceride Lowering by Nicotinic Acid
To determine the significance of the PGC-1b/APOC3 pathway in
mediating triglyceride-lowering effects of nicotinic acid, we414 Cell Metabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Intransduced mice fed control or 1% nicotinic acid-containing
chow with control or PGC-1b RNAi adenoviruses. While both
nicotinic acid feeding and PGC-1b knockdown reduce plasma
triglyceride levels, the combination of these two treatments
does not lead to a further decrease in plasma triglycerides (Fig-
ure 3F). Liver triglyceride content is not affected by these treat-
ments (data not shown). Real-time PCR analysis indicates that
hepatic expression of PGC-1b and APOC3 is reduced by nico-
tinic acid and PGC-1b shRNA (Figures 3G and 3H). Similarly,
adenoviral-mediated knockdown of APOC3 reduces plasma
triglyceride levels by approximately 38% (Figure 3I). This hypo-
triglyceridemic effect is not augmented in mice fed nicotinic
acid-containing chow, suggesting that downregulation of
APOC3 significantly contributes to the triglyceride-lowering
activity of nicotinic acid. Gene expression analyses revealed
that APOC3 mRNA level is reduced following nicotinic acid
and APOC3 shRNA treatments (Figure S2C). Interestingly,
PGC-1b expression appears to be slightly elevated when
APOC3 is knocked down in the liver. To examine whether
adenoviral-mediated expression of PGC-1b can block the
effects of nicotinic acid, we transduced control and nicotinic
acid-fed mice with GFP or PGC-1b adenoviruses. Nicotinic
acid feeding results in a 32% decrease in plasma triglyceride
levels in mice transduced with Ad-GFP. In contrast, adeno-
viral-mediated expression of PGC-1b in the liver blocks the
ability of nicotinic acid to lower plasma triglycerides (Figure S2D).
Together, these results suggest that hepatic PGC-1b/APOC3
pathway is a major contributor to the therapeutic action of nico-
tinic acid.
Analyses of Hepatic PGC-1b Transcriptional Complex
in the Regulation of APOC3 Expression
PGC-1b functions through interacting with transcription factors
as well as chromatin-remodeling cofactors, including LXR,
SREBP, PPARa, and Foxa2, in the regulation of hepatic metab-
olism (Lin et al., 2003, 2005b; Wolfrum and Stoffel, 2006). To
date, the components of the PGC-1b transcriptional complex
in the liver remain to be elucidated. To identify novel factors
associated with PGC-1b, we used a recombinant adenoviral
vector to direct the expression of Flag- and HA-tagged
PGC-1b in mouse livers. We purified the PGC-1b transcriptional
complex from liver nuclear extracts with anti-Flag and anti-HA
affinity matrix and identified individual proteins usingmass spec-
trometry. PGC-1b is present in a nearly stoichiometric manner
with ERRa, an orphan nuclear receptor that has been shown to
physically interact with PGC-1b (Kamei et al., 2003) (Figure 4A).
In addition, we identified several chromatin-remodeling factors
in this complex, including host cell factor 1 (HCF1) and CBP/
p300 histone acetyltransferase, as well as TRRAP, a component
of the mediator complex. The presence of TRRAP, p300, and
ERRa in the PGC-1b transcriptional complex was further
confirmed in immunoblotting analyses using specific antibodies
against these factors (Figure 4A).
To investigate the role of PGC-1b and its associated proteins
in APOC3 gene transcription, we constructed a luciferase
reporter plasmid that contains 1.5 kb upstream of the transcrip-
tional start site of mouse APOC3 gene. As shown in Figure 4B,
PGC-1b stimulates APOC3 promoter activity in transiently
transfected hepatoma cells in a dose-dependent manner. Whilec.
Figure 3. Role of PGC-1b and APOC3 in Mediating Triglyceride-Lowering Effects of Nicotinic Acid
(A) Real-time PCR analysis of total liver RNA from mice treated with vehicle (open, saline) or nicotinic acid (filled, 100 mg/kg, i.p.) for 2 or 4 hr. *p < 0.01.
(B) Immunoblotting analysis of liver nuclear extracts from mice treated with vehicle (Veh) or nicotinic acid (NA) for 4 hr.
(C) Plasma triglyceride and NEFA concentrations in mice fed a high-fat diet containing no (open) or 1% (filled) nicotinic acid for 3 months (n = 5). **p < 0.01.
(D) Immunoblotting analysis of APOC3 and PGC-1b in serum samples and liver nuclear extracts, respectively.
(E) Real-time PCR analysis of liver gene expression in mice in (C). *p < 0.05; **p < 0.01; ***p < 0.001.
(F) Plasma triglyceride concentrations. C57BL/6J male mice were fed control (filled) or chow containing 1% nicotinic acid (open) for 2 weeks and transduced with
scrb or siPGC-1b adenoviruses for 5 days, as indicated.
(G) Real-time PCR analysis of liver gene expression. Data in (F) and (G) represent mean ± SEM (n = 4–5). *p < 0.05 Veh versus NA.
(H) Immunoblots of PGC-1b and Lamin in liver nuclear extracts from mice in (F). Note that PGC-1b is reduced in response to NA treatment and PGC-1b shRNA.
(I) Shown are plasma triglyceride and NEFA concentrations and liver triglyceride content. C57BL/6J male mice were fed control (filled) or chow containing 1%
nicotinic acid (open) for 2 weeks and transduced with scrb or siAPOC3 adenoviruses for 5 days. Data represent mean ± SEM (n = 7–8). *p < 0.05 Veh versus
NA; **p < 0.01 scrb versus siAPOC3. See also Figure S2.
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potentiates the ability of PGC-1b to transactivate the APOC3
promoter. Similarly, CBP and HCF1 also augment the stimula-
tory effects of PGC-1b on this reporter (Figure 4C). Previous
studies have demonstrated that APOC3 promoter is regulated
by several transcription factors, including HNF4a, RORa,
RXR, and FoxO1 (Altomonte et al., 2004; Mishiro et al., 2009;
Raspe et al., 2001; Vu-Dac et al., 1998; Zannis et al., 2001).
Our results suggest that PGC-1b may coactivate ERRa on
the APOC3 promoter and recruit additional chromatin-remodel-
ing factors to stimulate its transcription. Previous work has
identified a transcriptional enhancer located upstream of the
APOC3 gene (Bisaha et al., 1995). We found that two putative
ERRa-binding sites (ERRE) are located within the enhancerCelland the proximal promoter regions (Figure 4D). The ERRE in
the enhancer was previously shown to regulate APOA4 gene
expression (Carrier et al., 2004). Chromatin immunoprecipita-
tion (ChIP) assays indicate that PGC-1b is recruited to the prox-
imity of these ERRa-binding sites. Coactivation studies using
truncated mutant promoters indicate that the enhancer
sequence is required for the synergistic activation of APOC3
reporter activity by ERRa and PGC-1b (Figure 4E). Consistently,
mutation of ERRE in the enhancer region severely diminished
the ability of PGC-1b to coactivate ERRa on the APOC3
promoter (Figure 4F). These results identified ERRa and
chromatin-remodeling cofactors as components of the
PGC-1b transcriptional complex that regulates APOC3 gene
transcription.Metabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Inc. 415
Figure 4. Regulation of APOC3 Gene Expression by the PGC-1b Transcriptional Complex
(A) Identification of proteins in the PGC-1b transcriptional complex. Affinity-purified complexes from livers of mice transduced with Ad-GFP or Ad-PGC-1bwere
separated by SDS-PAGE. Individual bands were excised and proteins identified by mass spectrometry (left panel). Immunoblotting analysis of the PGC-1b
complex using indicated antibodies (right panel).
(B) Coactivation assays of mouse APOC3 promoter with different amounts of PGC-1b plasmid in the presence or absence of ERRa in transiently transfected
McArdle RH7777 hepatoma cells.
(C) Coactivation analysis of the mouse APOC3 gene promoter by PGC-1b, HCF1, and CBP. For (B) and (C), shown are representative experiments from at least
three independent experiments. Data represent mean ± SD.
(D) ChIP analysis. Chromatin extracts from transduced livers were immunoprecipitated with anti-PGC-1b antibody or IgG. The precipitated genomic DNA were
PCR amplified using primers flanking ERRE located in the enhancer and proximal promoter regions.
(E) Coactivation assays of truncated APOC3 promoter reporters. RH7777 cells were transiently transfected with reporter constructs spanning 1.5 kb, 750 bp
(enhancer and promoter regions, E/P), or 350 bp (proximal promoter only, P) in combination with ERRa in the presence or absence of PGC-1b.
(F) Coactivation assays of APOC3 reporter constructs with mutant ERRE. For (E) and (F), shown are representative experiments from at least three independent
experiments. Data represent mean ± SD.
(G) Model illustrating the PGC-1b/APOC3 pathway in mediating the hypolipidemic effects of nicotinic acid.
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We identified the PGC-1b/APOC3 pathway as a hepatic target of
nicotinic acid that mediates its triglyceride-lowering effects
(Figure 4G). Nicotinic acid signals through its receptor on adipo-
cytes, leading to inhibition of lipolysis and lower circulating NEFA
levels. The latter decreases the expression of PGC-1b and its
target gene APOC3 in the liver and reduces plasma APOC3
concentrations. Importantly, adenoviral-mediated knockdown
of PGC-1b or APOC3 does not further reduce plasma triglyceride
concentrations beyond nicotinic acid treatments. These findings
suggest that the suppression of PGC-1b and APOC3 in the liver416 Cell Metabolism 12, 411–419, October 6, 2010 ª2010 Elsevier Inis responsible for a significant portion of the therapeutic activity
of nicotinic acid.
Genetic polymorphisms within the APOA1/C3/A4/A5 gene
cluster confer significant risk for hypertriglyceridemia in humans.
Our studies indicate that PGC-1b is a key component of the
regulatory network that governs apolipoprotein gene expression
within this locus. First, PGC-1b differentially regulates the
expression of APO genes in the liver. While PGC-1b reduces
mRNA levels of APOA5, APOA1, and APOA4 in transduced
mouse liver, it stimulates APOC3 expression and significantly
elevates plasma APOC3 levels. The dichotomous effects of
PGC-1b on APOC3 and APOA5 expression are consistent withc.
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functional level, RNAi knockdown of APOC3 expression in the
liver blunts the hypertriglyceridemic effect of PGC-1b, whereas
re-expression of APOC3 blocks lipid-lowering effects of
PGC-1b shRNA. We previously demonstrated that PGC-1b
mediates hyperlipidemic effects of dietary fats through induction
of hepatic lipogenesis and VLDL secretion (Lin et al., 2005b). Our
current study indicates that PGC-1b also modulates catabolism
of VLDL triglycerides via its regulation of APOC3. In addition, this
regulatory pathway appears to be functional under both chow
and high-fat dietary conditions. The exact molecular mecha-
nisms that mediate the suppression of APOA5 by PGC-1b
remain unknown. It is possible that PGC-1b alters local chro-
matin structure in a manner that favors transcriptional activation
of the APOC3 gene. Alternatively, PGC-1b may function as
a transcriptional repressor and directly inhibits APOA5 transcrip-
tion. Given the strong association of genetic polymorphisms
within the APOA1/C3/A4/A5 locus and plasma triglyceride
concentrations in humans, it is possible that transcriptional regu-
lation by PGC-1b may underlie the influence of certain genetic
polymorphisms on hypertriglyceridemia. Future work should
address whether PGC-1b differentially regulates APO gene
expression on distinct polymorphic alleles.
Recent studies have identified GPR109A, a Gi-coupled
receptor, as the molecular target that mediates the therapeutic
function as well as certain side effects of nicotinic acids (Benyo
et al., 2005; Tunaru et al., 2003). GPR109A is highly expressed in
the adipose tissue, and it negatively modulates lipolysis. Since
fatty acids provide key substrates for triglyceride synthesis in
the liver, a logical model for the hypotriglyceridemic activity of
nicotinic acid is that reduced flux of fatty acids leads to
decreased VLDL assembly and secretion (Gille et al., 2008;
Karpe and Frayn, 2004; Wang et al., 2001). Other targets that
mediate the therapeutic action of nicotinic acid have not been
identified. We found that acute and chronic nicotinic acid treat-
ments suppress hepatic PGC-1b and APOC3 gene expression.
These observations strongly suggest that nicotinic acid may
impinge on a broader program of lipid metabolism to achieve
its therapeutic benefits. In this case, inhibition of hepatic
PGC-1b and APOC3 is expected to lower plasma triglycerides
through reducing the production while enhancing the catabolism
of triglyceride-rich lipoproteins. Since nicotinic acid does not
appear to directly regulate PGC-1b in cultured primary hepato-
cytes, the inhibition of its expression is likely secondary to the
suppression of adipose lipolysis and reduced NEFA levels.
Proteomic analysis of the PGC-1b transcriptional complex in
the liver reveals surprising diversity of chromatin-remodeling
factors that stably associate with this coactivator. Similar to
PGC-1a, PGC-1b physically interacts with the CBP/p300 family
of histone acetyltransferases as well as TRRAP, a component of
the mediator complex (Puigserver et al., 1999; Wallberg et al.,
2003). In addition, PGC-1b associates with HCF1, a scaffold
protein that was previously found to interact with PGC-1 coacti-
vators and associate with histone methyltransferases (Lin et al.,
2002; Wysocka et al., 2003). As such, it is likely that the recruit-
ment of HCF1 to PGC-1b target genes leads to specific changes
in histone methylation patterns on their promoters. Notably, we
found that ERRa is the only DNA-binding transcription factor
that is abundantly and stably present in the PGC-1b proteinCellcomplex. This finding is consistent with the uniquely high affinity
between the PGC-1 coactivators and the ERR family of nuclear
receptors (Huss et al., 2002; Kamei et al., 2003; Schreiber
et al., 2003). At the molecular level, PGC-1b coactivates ERRa
to stimulate APOC3 promoter activity, primarily through an
ERRa-binding site located within the APOC3 enhancer. Because
PGC-1b differentially regulates genes within the APOA1/C3/A4/
A5 locus, it is possible that this coactivator participates in the
formation of higher-order regulatory complexes that exert both
positive and negative regulation on individual apolipoprotein
genes.
EXPERIMENTAL PROCEDURES
In Vivo Adenoviral Transduction and Metabolic Analyses
C57BL/6J male mice were transduced with purified adenoviruses through tail
vein injection (0.15 OD per mouse), as previously described (Li et al., 2008). All
adenoviruses were titered in mice and monitored for the expression of GFP
and adenoviral gene AdE4 to ensure similar doses were administered in meta-
bolic studies. For nicotinic acid feeding, rodent chow (Harlan Teklad, #7012)
was mixed with the compound at 1% (w/w), as previously described (Hernan-
dez et al., 2007). Plasma triglyceride and NEFA concentrations weremeasured
5–7 days following transduction using commercial assay kits (Sigma, Wako
Diagnostics). Hepatic gene expression was analyzed by qPCR using specific
primers (Table S1). For lipoprotein profile analysis, pooled plasma samples
from two transduced mice were fractionated by fast protein liquid chromato-
graphy. The concentrations of triglyceride and cholesterol in each fraction
were analyzed.
Affinity Purification of PGC-1b Transcriptional Complex
Liver nuclear extract was prepared from ten mice transduced with Ad-GFP or
Ad-Flag/HA-PGC-1b adenoviruses. Sequential steps of immunoprecipitation
were performed using anti-Flag (Sigma) and anti-HA (Roche) affinity matrix fol-
lowed by eluting with 50 mg/ml Flag and HA peptides, respectively. Eluted
protein complex was analyzed by SDS-PAGE. Following colloidal blue stain-
ing, individual bandswere excised for protein identification bymass spectrom-
etry. Immunoblotting was performed using anti-p300 (sc-584, Santa Cruz
Biotechnology), anti-ERRa (ab16363, Abcam), and anti-TRRAP (sc-11411),
anti-APOC3 (sc-50378), anti-APOB48/APOB100 (K23300R, Biodesign), anti-
Lamin (Cell Signaling, #2032), and anti-PGC-1b antibodies.
ChIP Assay
ChIP was performed essentially as described (Li et al., 2008). For chromatin
lysates from mouse livers, liver nuclei were isolated and then crosslinked in
1% formaldehyde for 10 min followed by sonication. After being precleared
with protein G agarose beads, chromatin lysates were immunoprecipitated
using antibodies against PGC-1b or control rabbit IgG in the presence of
BSA and salmon sperm DNA. Beads were extensively washed before reverse
cross-linking. DNA was purified using a purification kit (QIAGEN) and subse-
quently analyzed by PCR using primers flanking the enhancer or the proximal
promoter regions (Table S1).
Reporter Gene Assays
Rat McArdle RH7777 hepatoma cells were transiently transfected with indi-
cated plasmids using Lipofectamine. Equal amounts of DNA were used for
all transfection combinations by adding appropriate vector DNA. Relative lucif-
erase activities were determined 48 hr following transfection. All transfection
experiments were repeated at least three times in duplicates. Data represent
mean ± SEM.
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